三生制药(01530)发布年度业绩股东应占纯利增加305.8%至84.82亿元

智通财经

Mar 30

智通财经APP讯，三生制药(01530)发布截至2025年12月31日止年度全年业绩，集团收入增加94.3%至人民币176.96亿元。毛利增加108.8%至人民币163.47亿元，毛利率为92.4%。母公司拥有人应占纯利增加305.8%至人民币84.82亿元。末期股息每股25港仙。

三生制药为中国内地领先的生物技术公司。本集团作为中国生物技术行业的先锋，在研发、生产及营销生物医药产品方面拥有丰富的经验。本集团的核心商业化产品包括多种生物药物，即特比澳、重组人促红素(“rhEPO”)产品益比奥及赛博尔、益赛普和赛普汀，以及小分子药物蔓迪产品管线的米诺地尔药物系列。特比澳为当今全球唯一商业化的重组人血小板生成素(“rhTPO”)产品。根据IQVIA，于2025年，按销售额计，特比澳在中国内地血小板减少症治疗市场的份额为60.4%。凭借两种rhEPO产品，二十多年来，本集团一直为中国内地rhEPO市场龙头，于2025年共占39.6%的总市场份额。益赛普为中国内地市场推出的首个肿瘤坏死因子(“TNF”)α抑制剂产品。蔓迪在中国内地防脱发药物市场亦占主导地位。本集团亦通过内部研究及开发(“研发”)及多项外部战略合作增加产品以扩大治疗领域。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2623496733"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623496733\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623496733?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-30 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623496733","market":"sh","top_or_hot":-1,"title":"三生制药(01530)发布年度业绩 股东应占纯利增加305.8%至84.82亿元","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/01530\">三生制药</a>(01530)发布截至2025年12月31日止年度全年业绩，集团收入增加94.3%至人民币176.96亿元。毛利增加108.8%至人民币163.47亿元，毛利率为92.4%。母公司拥有人应占纯利增加305.8%至人民币84.82亿元。末期股息每股25港仙。</p><p>三生制药为中国内地领先的生物技术公司。本集团作为中国生物技术行业的先锋，在研发、生产及营销生物医药产品方面拥有丰富的经验。本集团的核心商业化产品包括多种生物药物，即特比澳、重组人促红素(“rhEPO”)产品益比奥及赛博尔、益赛普和赛普汀，以及小分子药物蔓迪产品管线的米诺地尔药物系列。特比澳为当今全球唯一商业化的重组人血小板生成素(“rhTPO”)产品。根据IQVIA，于2025年，按销售额计，特比澳在中国内地血小板减少症治疗市场的份额为60.4%。凭借两种rhEPO产品，二十多年来，本集团一直为中国内地rhEPO市场龙头，于2025年共占39.6%的总市场份额。益赛普为中国内地市场推出的首个肿瘤坏死因子(“TNF”)α抑制剂产品。蔓迪在中国内地防脱发药物市场亦占主导地位。本集团亦通过内部研究及开发(“研发”)及多项外部战略合作增加产品以扩大治疗领域。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>三生制药(01530)发布年度业绩 股东应占纯利增加305.8%至84.82亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n三生制药(01530)发布年度业绩 股东应占纯利增加305.8%至84.82亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 22:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1422212.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，三生制药(01530)发布截至2025年12月31日止年度全年业绩，集团收入增加94.3%至人民币176.96亿元。毛利增加108.8%至人民币163.47亿元，毛利率为92.4%。母公司拥有人应占纯利增加305.8%至人民币84.82亿元。末期股息每股25港仙。三生制药为中国内地领先的生物技术公司。本集团作为中国生物技术行业的先锋，在研发、生产及营销生物医药产品方面拥有丰富的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1422212.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1422212.html","article_id":"2623496733","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623496733","pubTimestamp":1774880949,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，三生制药 发布截至2025年12月31日止年度全年业绩，集团收入增加94.3%至人民币176.96亿元。毛利增加108.8%至人民币163.47亿元，毛利率为92.4%。母公司拥有人应占纯利增加305.8%至人民币84.82亿元。末期股息每股25港仙。根据IQVIA，于2025年，按销售额计，特比澳在中国内地血小板减少症治疗市场的份额为60.4%。凭借两种rhEPO产品，二十多年来，本集团一直为中国内地rhEPO市场龙头，于2025年共占39.6%的总市场份额。蔓迪在中国内地防脱发药物市场亦占主导地位。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1593":"医美概念股","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1161":"生物科技","01530":"三生制药","BK1583":"高瓴概念"},"translate_title":"3SBio (01530) released its annual results Net profit attributable to shareholders increased by 305.8% to 8.482 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1.5},"content_text":"智通财经APP讯，三生制药(01530)发布截至2025年12月31日止年度全年业绩，集团收入增加94.3%至人民币176.96亿元。毛利增加108.8%至人民币163.47亿元，毛利率为92.4%。母公司拥有人应占纯利增加305.8%至人民币84.82亿元。末期股息每股25港仙。三生制药为中国内地领先的生物技术公司。本集团作为中国生物技术行业的先锋，在研发、生产及营销生物医药产品方面拥有丰富的经验。本集团的核心商业化产品包括多种生物药物，即特比澳、重组人促红素(“rhEPO”)产品益比奥及赛博尔、益赛普和赛普汀，以及小分子药物蔓迪产品管线的米诺地尔药物系列。特比澳为当今全球唯一商业化的重组人血小板生成素(“rhTPO”)产品。根据IQVIA，于2025年，按销售额计，特比澳在中国内地血小板减少症治疗市场的份额为60.4%。凭借两种rhEPO产品，二十多年来，本集团一直为中国内地rhEPO市场龙头，于2025年共占39.6%的总市场份额。益赛普为中国内地市场推出的首个肿瘤坏死因子(“TNF”)α抑制剂产品。蔓迪在中国内地防脱发药物市场亦占主导地位。本集团亦通过内部研究及开发(“研发”)及多项外部战略合作增加产品以扩大治疗领域。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}